Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions

International Journal of Legal Medicine

Volumn 125, Issue 3, 2011, Pages 349-358

  Launiainen, Terhi ^a   Rasanen, Ilpo ^a   Vuori, Erkki ^a   Ojanperä, Ilkka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP2D6; Pharmacogenetics; Post mortem database; Venlafaxine; Venlafaxine metabolite

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; CYTOCHROME P450 2D6; DESVENLAFAXINE; N DESMETHYLVENLAFAXINE; N-DESMETHYLVENLAFAXINE; O-DESMETHYLVENLAFAXINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; DRUG INTERACTION; FACTUAL DATABASE; FEMALE; FORENSIC PATHOLOGY; GENETICS; GENOTYPE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DATABASES, FACTUAL; DRUG INTERACTIONS; FEMALE; FORENSIC PATHOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 79956155913     PISSN: 09379827     EISSN: 14371596     Source Type: Journal    
DOI: 10.1007/s00414-010-0461-5     Document Type: Article

References (55)

1. SM Holliday P Benfield 1995 Venlafaxine. A review of its pharmacology and therapeutic potential in depression Drugs 49 280 294 7729333 10.2165/00003495-199549020-00010 1:CAS:528:DyaK2MXkt1Citbg%3D
2. SV Otton SE Ball SW Cheung T Inaba RL Rudolph EM Sellers 1996 Venlafaxine oxidation in vitro is catalysed by CYP2D6 Br J Clin Pharmacol 41 149 156 8838442 10.1111/j.1365-2125.1996.tb00173.x 1:CAS:528:DyaK28Xhs1Oht7Y%3D (Pubitemid 26060742)
3. SM Fogelman J Schmider K Venkatakrishnan LL von Moltke JS Harmatz RI Shader DJ Greenblatt 1999 O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants Neuropsychopharmacology 20 480 490 10192828 10.1016/S0893-133X(98)00113-4 1:CAS:528:DyaK1MXit1Oht7s%3D (Pubitemid 29123875)
4. L Ereshefsky D Dugan 2000 Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine Depress Anxiety 12 Suppl 1 30 44 11098412 10.1002/1520-6394(2000)12: 1+<30::AID-DA4>3.0.CO;2-G
5. CB Eap E Lessard P Baumann M Brawand-Amey G O'Hara J Turgeon 2003 Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans Pharmacogenetics 13 39 47 12544511 10.1097/00008571-200301000-00006 1:CAS:528:DC%2BD3sXlsFGqsg%3D%3D (Pubitemid 36135685)
6. J Sistonen S Fuselli JU Palo N Chauhan H Padh A Sajantila 2009 Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 19 170 179 19151603 10.1097/FPC.0b013e32831ebb30 1:CAS:528:DC%2BD1MXmvVartg%3D%3D
7. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 229 243 11972444 10.1517/14622416.3.2.229 1:CAS:528:DC%2BD38XitlWqu70%3D (Pubitemid 34223859)
8. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Pharmacol 369 23 37 14618296 10.1007/s00210-003-0832-2 1:CAS:528: DC%2BD2cXitF2hsQ%3D%3D (Pubitemid 38161221)
9. M Hermann M Hendset K Fosaas M Hjerpset H Refsum 2008 Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D63,4 or5 allele Eur J Clin Pharmacol 64 483 487 18214456 10.1007/s00228-007-0453-7 1:CAS:528:DC%2BD1cXjsVCrtbg%3D
10. J Kirchheiner K Nickchen M Bauer ML Wong J Licinio I Roots J Brockmoller 2004 Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 442 473 15037866 10.1038/sj.mp.4001494 1:CAS:528:DC%2BD2cXjsV2nu70%3D (Pubitemid 38903502)
11. ME Shams B Arneth C Hiemke A Dragicevic MJ Muller R Kaiser K Lackner S Hartter 2006 CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J Clin Pharm Ther 31 493 502 16958828 10.1111/j.1365-2710.2006. 00763.x 1:CAS:528:DC%2BD28XhtF2mu7rK (Pubitemid 44337299)
12. NJ Langford U Martin M Ruprah RE Ferner 2002 Alternative venlafaxine kinetics in overdose J Clin Pharm Ther 27 465 467 12472987 10.1046/j.1365-2710. 2002.00438.x 1:STN:280:DC%2BD3s%2FhtVSjsQ%3D%3D (Pubitemid 35463900)
13. E Lessard MA Yessine BA Hamelin G O'Hara J LeBlanc J Turgeon 1999 Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans Pharmacogenetics 9 435 443 10780263 10.1097/00008571-199912000-00003 1:CAS:528:DyaK1MXmtlGjsrY%3D (Pubitemid 29419562)
14. C Kawanishi S Lundgren H Agren L Bertilsson 2004 Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study Eur J Clin Pharmacol 59 803 807 14652703 10.1007/s00228-003-0701-4 1:CAS:528:DC%2BD2cXovVGltQ%3D%3D (Pubitemid 38221657)
15. EM Whyte M Romkes BH Mulsant MA Kirshne AE Begley CF Reynolds 3rd BG Pollock 2006 CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly Int J Geriatr Psychiatry 21 542 549 16642541 10.1002/gps.1522 (Pubitemid 44043755)
16. J van der Weide EH van Baalen-Benedek JE Kootstra-Ros 2005 Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype Ther Drug Monit 27 478 483 16044105 10.1097/01.ftd.0000162868.84596.c3 (Pubitemid 41098823)
17. A Öhberg E Vuori I Ojanpera J Lonngvist 1996 Alcohol and drugs in suicides Br J Psychiatry 169 75 80 8818372 10.1192/bjp.169.1.75
18. A Koski E Vuori I Ojanpera 2005 Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data Int J Leg Med 119 344 348 10.1007/s00414-005-0528-x (Pubitemid 41586728)
19. S Cheeta F Schifano A Oyefeso L Webb AH Ghodse 2004 Antidepressant- related deaths and antidepressant prescriptions in England and Wales, 1998-2000 Br J Psychiatry 184 41 47 14702226 10.1192/bjp.184.1.41 (Pubitemid 38085213)
20. O Morgan C Griffiths A Baker A Majeed 2004 Fatal toxicity of antidepressants in England and Wales, 1993-2002 Health Stat Q 23 18 24 15704381
21. NA Buckley PR McManus 2002 Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data BMJ 325 1332 1333 12468481 10.1136/bmj.325.7376.1332 (Pubitemid 35471550)
22. GM Bosse HA Spiller AM Collins 2008 A fatal case of venlafaxine overdose J Med Toxicol 4 18 20 18338306 10.1007/BF03160945
23. C Howell AD Wilson WS Waring 2007 Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases Br J Clin Pharmacol 64 192 197 17298480 10.1111/j.1365-2125.2007.02849.x 1:CAS:528:DC%2BD2sXpslGlt78%3D (Pubitemid 47063239)
24. B Megarbane V Bloch N Deye FJ Baud 2007 Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose Intensive Care Med 33 195 196 17102961 10.1007/s00134-006-0419-8 author reply 197 (Pubitemid 46115489)
25. M Roxanas E Hibbert M Field 2007 Venlafaxine hyponatraemia: incidence, mechanism and management Aust N Z J Psychiatry 41 411 418 17464733 10.1080/00048670701261202 (Pubitemid 46705715)
26. C Egger M Muehlbacher M Nickel C Geretsegger C Stuppaeck 2006 A case of recurrent hyponatremia induced by venlafaxine J Clin Psychopharmacol 26 439 16855472 10.1097/01.jcp.0000229934.83564.ef (Pubitemid 44187655)
27. CA Kelly N Dhaun WJ Laing FE Strachan AM Good DN Bateman 2004 Comparative toxicity of citalopram and the newer antidepressants after overdose J Toxicol Clin Toxicol 42 67 71 15083939 10.1081/CLT-120028747 1:CAS:528: DC%2BD2cXitFygu7w%3D (Pubitemid 38450941)
28. IM Whyte AH Dawson NA Buckley 2003 Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants QJM 96 369 374 12702786 10.1093/qjmed/hcg062 1:STN:280:DC%2BD3s3ivFahsQ%3D%3D (Pubitemid 36592709)
29. AD Wilson C Howell WS Waring 2007 Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series J Toxicol Sci 32 97 101 17327698 10.2131/jts.32.97 1:CAS:528:DC%2BD2sXltFWltLY%3D (Pubitemid 46334074)
30. G Gartlehner P Thieda RA Hansen BN Gaynes A Deveaugh-Geiss EE Krebs KN Lohr 2008 Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis Drug Saf 31 851 865 18759509 10.2165/00002018-200831100-00004 1:CAS:528:DC%2BD1cXht1yisrvE
31. S Weinmann T Becker M Koesters 2008 Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis Psychopharmacology (Berl) 196 511 520 10.1007/s00213-007-0975-9 1:CAS:528:DC%2BD1cXhvFykuro%3D (Pubitemid 351623005)
32. SM Stahl MM Grady C Moret M Briley 2005 SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants CNS Spectr 10 732 747 16142213 (Pubitemid 41443048)
33. D Brent G Emslie G Clarke KD Wagner JR Asarnow M Keller B Vitiello L Ritz S Iyengar K Abebe B Birmaher N Ryan B Kennard C Hughes L DeBar J McCracken M Strober R Suddath A Spirito H Leonard N Melhem G Porta M Onorato J Zelazny 2008 Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial JAMA 299 901 913 18314433 10.1001/jama.299.8.901 1:CAS:528:DC%2BD1cXis1Cgs7g%3D (Pubitemid 351397065)
34. M Bauer P Tharmanathan HP Volz HJ Moeller N Freemantle 2009 The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis Eur Arch Psychiatry Clin Neurosci Doi: 10.1007/s00406-008-0849-0
35. D Mines D Hill H Yu L Novelli 2005 Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram Pharmacoepidemiol Drug Saf 14 367 372 15883980 10.1002/pds.1095 (Pubitemid 40895543)
36. I Rasanen I Kontinen J Nokua I Ojanpera E Vuori 2003 Precise gas chromatography with retention time locking in comprehensive toxicological screening for drugs in blood J Chromatogr B Analyt Technol Biomed Life Sci 788 243 250 12705964 10.1016/S1570-0232(02)01012-7 1:CAS:528:DC%2BD3sXivFCrsrs%3D (Pubitemid 36428527)
37. J Sistonen S Fuselli A Levo A Sajantila 2005 CYP2D6 genotyping by a multiplex primer extension reaction Clin Chem 51 1291 1295 15905314 10.1373/clinchem.2004.046466 1:CAS:528:DC%2BD2MXlsleqsbs%3D (Pubitemid 43079419)
38. J Strandell A Bate M Lindquist IR Edwards Swedish, Finnish, Interaction X-referencing Drug-drug Interaction Database (SFINX Group) 2008 Drug-drug interactions-a preventable patient safety issue? Br J Clin Pharmacol 65 144 146 17635497 10.1111/j.1365-2125.2007.02981.x (Pubitemid 350265169)
39. A Gaedigk SD Simon RE Pearce LD Bradford MJ Kennedy JS Leeder 2008 The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242 17971818 10.1038/sj.clpt.6100406 1:STN:280:DC%2BD1c%2FkslCqug%3D%3D
40. Moffat AC, Osselton MD, Widdop B (eds) (2004) Clarke's analysis of drugs and poisons, 3rd edn. UK, Pharmaceutical Press, London
41. E Vuori I Ojanperä J Nokua RL Ojansivu 2006 Oikeuskemiallisesti todetut myrkytyskuolemat Suomessa vuosina 2002-2004 Suomen lääkä rilehti (Finnish Medical Journal) 61 2339 2344 in Finnish, English summary: Fatal poisonings in Finland 2002-2004
42. M Reis T Aamo J Ahlner H Druid 2007 Reference concentrations of antidepressants A compilation of postmortem and therapeutic levels J Anal Toxicol 31 254 264 17579969 1:CAS:528:DC%2BD2sXmt1Gms7s%3D (Pubitemid 46911622)
43. KE Goeringer IM McIntyre OH Drummer 2001 Postmortem tissue concentrations of venlafaxine Forensic Sci Int 121 70 75 11516890 10.1016/S0379-0738(01)00455- 8 1:CAS:528:DC%2BD3MXmtV2nurc%3D (Pubitemid 32758816)
44. PD Jaffe HP Batziris P van der Hoeven D DeSilva IM McIntyre 1999 A study involving venlafaxine overdoses: comparison of fatal and therapeutic concentrations in postmortem specimens J Forensic Sci 44 193 196 9987886 1:CAS:528:DC%2BD3cXptFOrtg%3D%3D (Pubitemid 29035792)
45. T Launiainen E Vuori I Ojanpera 2009 Prevalence of adverse drug combinations in a large post-mortem toxicology database Int J Leg Med 123 109 115 10.1007/s00414-008-0261-3
46. D Deshauer 2007 Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose CMAJ 176 39 40 17167104 (Pubitemid 46144741)
47. ST Saarikoski F Sata K Husgafvel-Pursiainen M Rautalahti J Haukka O Impivaara J Jarvisalo H Vainio A Hirvonen 2000 CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour Pharmacogenetics 10 5 10 10739167 10.1097/00008571-200002000-00002 1:CAS:528:DC%2BD3cXhvFGitLk%3D (Pubitemid 30142808)
48. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526 18001838 10.1016/j.pharmthera.2007.09.004 1:CAS:528:DC%2BD2sXhtlCrs7bE (Pubitemid 350116943)
49. ML Dahl I Johansson L Bertilsson M Ingelman-Sundberg F Sjoqvist 1995 Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis J Pharmacol Exp Ther 274 516 520 7616439 1:CAS:528:DyaK2MXntVWlu7w%3D
50. R Løvlie AK Daly GE Matre A Molven VM Steen 2001 Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D635 allele in ultrarapid metabolism? Pharmacogenetics 11 45 55 11207030 10.1097/00008571-200102000-00006 (Pubitemid 32108661)
51. M Hendset T Haslemo I Rudberg H Refsum E Molden 2006 The complexity of active metabolites in therapeutic drug monitoring of psychotrophic drugs Pharmacopsychiatry 39 121 127 16871467 10.1055/s-2006-946701 1:CAS:528:DC%2BD28XovFWrtbk%3D (Pubitemid 44199179)
52. RJ Flanagan 2008 Fatal toxicity of drugs used in psychiatry Hum Psychopharmacol 23 Suppl 1 43 51 18098225 10.1002/hup.916 (Pubitemid 351166611)
53. KE Rodda OH Drummer 2006 The redistribution of selected psychiatric drugs in post-mortem cases Forensic Sci Int 164 235 239 16554130 10.1016/j.forsciint. 2006.02.013 1:CAS:528:DC%2BD28XhtFKmtrbK (Pubitemid 44667368)
54. B Levine AJ Jenkins M Queen R Jufer JE Smialek 1996 Distribution of venlafaxine in three postmortem cases J Anal Toxicol 20 502 505 8889688 1:CAS:528:DyaK28XlvF2rurY%3D (Pubitemid 26327474)
55. M Reis J Lundmark H Björk F Bengtsson 2002 Therapeutic drug monitoring of racemic venlafaxine and its metabolites in an everyday clinical setting Ther Drug Monit 24 545 553 12142641 10.1097/00007691-200208000-00014 1:CAS:528:DC%2BD38XmsValu7o%3D (Pubitemid 34857910)